The North America Gabapentin Market would witness market growth of 3.8% CAGR during the forecast period (2022-2028).
Gabapentin is one of the two medications used in the PROMETA protocol of treatment for methamphetamine, cocaine, and alcohol addiction. When taken in a dosage of 1200 milligrams, reports indicate that gabapentin has the potential to minimize the severity of symptoms of withdrawal as well as cravings caused by stopping the intake or usage of methamphetamine. Also, it minimizes the symptoms of withdrawal and assists those who are addicted to the medicines that are prescribed.
In addition, gabapentin has recently been shown to be effective in treating various conditions related to the nervous system. In recent years, gabapentin has become one of the most consumed and prescribed drugs. The increasing use can be ascribed to elements like the rising prevalence of seizures and neuropathic pain, as well as the rising use of the medicine as a pain reliever. In addition, the growing elderly population, increased government activities, and pharmaceutical corporations' R&D spending are further motivators. Gabapentin is an anticonvulsant typically provided to people with epilepsy to control their seizure activity.
In North America, epilepsy care is hampered by the lack of quality, quantity, and availability of diagnostic tools, medications, specialists, resources, and facilities. There is little public knowledge of epilepsy, which is more prevalent than Parkinson's disease, multiple sclerosis, or autism. Consequently, in recent years, the regional governments have been putting more effort into raising awareness about epilepsy. Such efforts have resulted in greater attention to the care of epileptics, facilitating the ease of drug accessibility. Therefore, the growing demand for gabapentin to treat epilepsy will accelerate the market's growth in the coming years.
The US market dominated the North America Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $719.8 million by 2028. The Canada market is poised to grow at a CAGR of 6.2% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 5.2% during (2022 - 2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Gabapentin Market is Projected to reach USD 2.6 Billion by 2028, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Epilepsy
- Restless Legs Syndrome
- Neuropathic Pain
- Others
By Dosage Form
- Capsule
- Tablet
- Oral Solution
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Limited
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Aurobindo Pharma Limited
- Amneal Pharmaceuticals, Inc.
- Cipla Limited
- Apotex, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Gabapentin Market, by Application
1.4.2 North America Gabapentin Market, by Dosage Form
1.4.3 North America Gabapentin Market, by Distribution Channel
1.4.4 North America Gabapentin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Gabapentin Market by Application
3.1 North America Epilepsy Market by Country
3.2 North America Restless Legs Syndrome Market by Country
3.3 North America Neuropathic Pain Market by Country
3.4 North America Others Market by Country
Chapter 4. North America Gabapentin Market by Dosage Form
4.1 North America Capsule Market by Country
4.2 North America Tablet Market by Country
4.3 North America Oral Solution Market by Country
Chapter 5. North America Gabapentin Market by Distribution Channel
5.1 North America Hospital Pharmacy Market by Country
5.2 North America Retail Pharmacy Market by Country
5.3 North America Online Pharmacy Market by Country
Chapter 6. North America Gabapentin Market by Country
6.1 US Gabapentin Market
6.1.1 US Gabapentin Market by Application
6.1.2 US Gabapentin Market by Dosage Form
6.1.3 US Gabapentin Market by Distribution Channel
6.2 Canada Gabapentin Market
6.2.1 Canada Gabapentin Market by Application
6.2.2 Canada Gabapentin Market by Dosage Form
6.2.3 Canada Gabapentin Market by Distribution Channel
6.3 Mexico Gabapentin Market
6.3.1 Mexico Gabapentin Market by Application
6.3.2 Mexico Gabapentin Market by Dosage Form
6.3.3 Mexico Gabapentin Market by Distribution Channel
6.4 Rest of North America Gabapentin Market
6.4.1 Rest of North America Gabapentin Market by Application
6.4.2 Rest of North America Gabapentin Market by Dosage Form
6.4.3 Rest of North America Gabapentin Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Zydus Lifesciences Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Trials and approvals:
7.2 Glenmark Pharmaceuticals Limited
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expense
7.4 Sun Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Acquisition and Mergers:
7.5 Alkem Laboratories Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 Aurobindo Pharma Limited
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.8 Amneal Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expenses
7.9 Cipla Limited
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.10. Apotex, Inc.
7.10.1 Company Overview
TABLE 1 North America Gabapentin Market, 2018 - 2021, USD Million
TABLE 2 North America Gabapentin Market, 2022 - 2028, USD Million
TABLE 3 North America Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 4 North America Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 5 North America Epilepsy Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Epilepsy Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Restless Legs Syndrome Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Restless Legs Syndrome Market by Country, 2022 - 2028, USD Million
TABLE 9 North America Neuropathic Pain Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Neuropathic Pain Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 12 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 13 North America Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 14 North America Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 15 North America Capsule Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Capsule Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Tablet Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Tablet Market by Country, 2022 - 2028, USD Million
TABLE 19 North America Oral Solution Market by Country, 2018 - 2021, USD Million
TABLE 20 North America Oral Solution Market by Country, 2022 - 2028, USD Million
TABLE 21 North America Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 22 North America Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 23 North America Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 24 North America Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 25 North America Retail Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 26 North America Retail Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 27 North America Online Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 28 North America Online Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 29 North America Gabapentin Market by Country, 2018 - 2021, USD Million
TABLE 30 North America Gabapentin Market by Country, 2022 - 2028, USD Million
TABLE 31 US Gabapentin Market, 2018 - 2021, USD Million
TABLE 32 US Gabapentin Market, 2022 - 2028, USD Million
TABLE 33 US Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 34 US Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 35 US Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 36 US Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 37 US Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 38 US Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 39 Canada Gabapentin Market, 2018 - 2021, USD Million
TABLE 40 Canada Gabapentin Market, 2022 - 2028, USD Million
TABLE 41 Canada Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 42 Canada Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 43 Canada Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 44 Canada Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 45 Canada Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 46 Canada Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 47 Mexico Gabapentin Market, 2018 - 2021, USD Million
TABLE 48 Mexico Gabapentin Market, 2022 - 2028, USD Million
TABLE 49 Mexico Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 50 Mexico Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 51 Mexico Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 52 Mexico Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 53 Mexico Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 54 Mexico Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 55 Rest of North America Gabapentin Market, 2018 - 2021, USD Million
TABLE 56 Rest of North America Gabapentin Market, 2022 - 2028, USD Million
TABLE 57 Rest of North America Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 58 Rest of North America Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 59 Rest of North America Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 60 Rest of North America Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 61 Rest of North America Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 62 Rest of North America Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 63 Key Information – Zydus Lifesciences Ltd.
TABLE 64 Key Information – Glenmark Pharmaceuticals Limited
TABLE 65 Key Information – Pfizer, Inc.
TABLE 66 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 67 Key Information – Alkem Laboratories Ltd.
TABLE 68 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 69 key information – Aurobindo Pharma Limited
TABLE 70 Key Information – Amneal Pharmaceuticals, INc.
TABLE 71 Key Information – Cipla Limited
TABLE 72 Key Information – Apotex, Inc.
List of Figures
FIG 1 Methodology for the research